This site is intended for U.S. healthcare professionals.

Visit Pfizer Medical

Menu

Close

Sign InLog Out ProductsOrderMaterialsCo-pay Cards & Patient Savings OffersRequest SamplesHospital ProductsVaccinesPatient AssistancePfizer Oncology TogetherPfizer RxPathwaysPfizer Dermatology Patient AccessExplore ContentEventsMaterialsVideosContact

Menu

Close

HomeCDC RecommendationAbout RSVAbout ABRYSVO

About ABRYSVO

Efficacy ProfileImmunobridgingSafety ProfileDosing, Storage, & ReconstitutionPatient ProfilesOrder ABRYSVO

Order ABRYSVO

Order ABRYSVORefer ABRYSVOAccess & Support

Access & Support

Health Plan CoverageRequest a RepVaccine LocatorMaterialsVideos
Prescribing InformationIndicationsPatient SiteMaternal
ABRYSVO® provides your patients aged 60+ powerful protection against RSV1,2Choose ABRYSVO to help protect eligible patients from the threat of RSV1Efficacy View 2-Season Data LoadingPrimary endpoints in an RSV clinical trial of ~34,000 adults aged 60 years and older1* Symptoms include cough, wheezing, sputum production, shortness of breath, and tachypnea.1ReferencesEvaluable efficacy population. Median duration of efficacy follow-up was 7 months.1Vaccine efficacy, against RSV-LRTD, defined as the relative risk reduction of first episode of RSV-LRTD in the ABRYSVO group compared to the placebo group in the first RSV season, was assessed.1Study design

Pivotal phase 3 study: RENOIR

  • Multinational, multicenter, randomized, double-blind, placebo-controlled clinical trial to assess the efficacy and safety of ABRYSVO1
  • Adults aged 60 years and older (median age, 67 years) who were healthy or had stable chronic diseases1,3
  • ~37,000 participants were randomized 1:1 to receive ABRYSVO (120 μg, n=18,575) or placebo (n=18,288)1
  • Randomization was stratified by age group, and ABRYSVO was given to 18,575 patients between 60-69 years (n=11,620), 70-79 years (n=5,928), and ≥80 years (n=1,026)1​​​​
  • Prespecified underlying medical conditions included heart disease, lung disease, having ≥1 chronic cardiopulmonary conditions (asthma, COPD, or CHF), diabetes, liver disease, renal disease, or current tobacco use3
  • Participants were followed for up to 2 RSV seasons1
Primary endpoint3 
  • Relative risk reduction (vs placebo) of first episode of RSV-associated lower respiratory tract disease (RSV-LRTD) in the first RSV season‡
  • Endpoint was stratified by ≥2 and ≥3 lower respiratory symptoms (new or worsened, including: cough, wheezing, sputum production, shortness of breath, tachypnea)
ReferencesAs determined by positive RT-PCR test within 7 days of symptom onset and lasting more than 1 day during the same illness.1High-risk populations were included in the RENOIR study1,3Additional data from RENOIR – across 2 seasons1,4§Additional efficacy data for season 2 and across 2 seasons are not included in the USPI.
Subgroup VE was a descriptive analysis, and results should not be interpreted as efficacy in any subgroup.

 VE (RSV-LRTD with ≥3 symptoms across 2 seasons) in subgroups was1,4:
• RSV-A: 80.6% (95% CI: 52.9, 93.4)
• RSV-B: 86.4% (95% CI: 54.6, 97.4)
ReferencesRENOIR was a phase 3 pivotal study, and participants were followed for up to 2 RSV seasons.2Season 1 and season 2 vaccine efficacy estimates reflect efficacy data from 2 RSV seasons, from August 2021 through November 2023. Vaccine efficacy across 2 seasons reflects efficacy against first events occurring any time during season 1 and season 2.1,4Additional participants were included in the descriptive efficacy analysis for Season 1; ABRYSVO (n=18,058) and placebo (18,076). The median duration of follow-up for efficacy was 7.1 months.2CI=confidence interval; CHF=chronic heart failure; COPD=chronic obstructive pulmonary disease; LRTD=lower respiratory tract disease; RSV=respiratory syncytial virus; RT-PCR=reverse transcription-polymerase chain reaction; USPI=US Prescribing Information; VE=vaccine efficacy.Related ContentOrder ABRYSVOLoadingVaccine LocatorLoadingAbout ABRYSVO
Stay Informed
 Receive Updates About ABRYSVO    Register NowLoading Request a Pfizer Sales Representative  Connect NowLoading

Explore a range of resources related to ABRYSVO, including videos, information about upcoming events, and more.

View Resources

Stay Informed
 Receive Updates About ABRYSVO    Register NowLoading Request a Pfizer Sales Representative  Connect NowLoading

Explore a range of resources related to ABRYSVO, including videos, information about upcoming events, and more.

 View ResourcesLoading
Stay Informed
 Receive Updates About ABRYSVO    Register NowLoading Request a Pfizer Sales Representative  Connect NowLoading

Explore a range of resources related to ABRYSVO, including videos, information about upcoming events, and more.

View ResourcesLoading
References:Data on file. Pfizer Inc.ABRYSVO (Respiratory Syncytial Virus Vaccine) Prescribing Information. Pfizer Inc; January 2025.Melgar M, Britton A, Roper LE, et al. Use of respiratory syncytial virus vaccines in older adults: recommendations of the Advisory Committee on Immunization Practices — United States, 2023. MMWR Morb Mortal Wkly Rep. 2023;72(29):793-801.Walsh EE, Pérez Marc G, Falsey AR, et al. RENOIR trial — RSVpreF vaccine over two seasons. N Engl J Med. 2024;391(15):1459-1460.

To report an adverse event, please call 1-800-438-1985

Pfizer for Professionals 1-800-505-4426

This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.

© 2025 Pfizer Inc. All rights reserved.

PP-A1G-USA-1986
IndicationsABRYSVO is a vaccine indicated for:
  • active immunization for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in individuals 60 years of age and older
  • active immunization of pregnant individuals at 32 through 36 weeks gestational age for the prevention of LRTD and severe LRTD caused by RSV in infants from birth through 6 months of age
  • active immunization for the prevention of LRTD caused by RSV in individuals 18 through 59 years of age who are at increased risk for LRTD caused by RSV
Please click here for full Prescribing Information.
Important Safety Information
  • Do not administer ABRYSVO to individuals with a history of a severe allergic reaction (e.g., anaphylaxis) to any component of ABRYSVO
  • The results of a postmarketing observational study suggest an increased risk of Guillain-Barré syndrome during the 42 days following vaccination with ABRYSVO
  • A numerical imbalance in preterm births was observed compared to placebo in 2 clinical studies. Data are insufficient to establish or exclude a causal relationship between preterm birth and ABRYSVO. To avoid potential risk of preterm birth with use of ABRYSVO before 32 weeks of gestation, administer to pregnant individuals at 32 through 36 weeks gestational age
  • Appropriate medical treatment must be available in case of an anaphylactic reaction
  • Syncope (fainting) may occur in association with administration of injectable vaccines, including ABRYSVO. Procedures should be in place to avoid injury from fainting
  • Immunocompromised individuals, including those receiving immunosuppressive therapy, may have a diminished immune response to ABRYSVO
  • Vaccination with ABRYSVO may not protect all vaccine recipients
  • In clinical trials with adults aged 60+, the most commonly reported (≥10%) adverse reactions
were fatigue (15.7%), headache (12.9%), pain at the injection site (10.7%), and muscle pain (10.2%)
  • In clinical trials with adults aged 18-59, the most commonly reported (≥10%) adverse reactions were pain at the injection site (35.3%), muscle pain (24.4%), joint pain (12.4%), and nausea (11.8%)
  • In clinical trials with pregnant individuals, the most commonly reported (≥10%) adverse reactions
were pain at the injection site (40.6%), headache (31.0%), muscle pain (26.5%), and nausea (20.0%)
  • In clinical trials with infants born to pregnant individuals, low birth weight (5.1% ABRYSVO versus 4.4% placebo) and neonatal jaundice (7.2% ABRYSVO versus 6.7% placebo) were observed
Individuals who received ABRYSVO during pregnancy are encouraged to contact 1-800-616-3791 to enroll in a Pregnancy Exposure Registry.

Patients should always ask their healthcare providers for medical advice about adverse events. You are encouraged to report negative side effects of vaccines to the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Visit http://www.vaers.hhs.gov or call 1-800-822-7967.

Please see full Prescribing Information for ABRYSVO.IndicationsABRYSVO is a vaccine indicated for:
  • active immunization for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in individuals 60 years of age and older
     
  • active immunization of pregnant individuals at 32 through 36 weeks gestational age for the prevention of LRTD and severe LRTD caused by RSV in infants from birth through 6 months of age
     
  • active immunization for the prevention of LRTD caused by RSV in individuals 18 through 59 years of age who are at increased risk for LRTD caused by RSV
You are now leaving PfizerPro  
You are now leaving a Pfizer operated website. Links to all outside sites are provided as a resource to our visitors. Pfizer accepts no responsibility for the content of sites that are not owned and operated by Pfizer.

PP-MCL-USA-0367